<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TRC-10001006</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2010-09-07</date_registration>
      <primary_sponsor>Beijing Cancer Hospital/Peking University School of Oncology</primary_sponsor>
      <public_title>Clinical study of immune reconstitution by depletion of regulatory T lymphocyte followed by high dose chemotherapy and hematopoietic stem cell rescue among metastatic breast cancer patients</public_title>
      <acronym />
      <scientific_title>Clinical study of immune reconstitution by depletion of regulatory T lymphocyte followed by high dose chemotherapy and hematopoietic stem cell rescue among metastatic breast cancer patients</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2010-09-15</date_enrolment>
      <type_enrolment />
      <target_size>A:40;B:40;C:40;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=8532</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>I (Phase I study)</phase>
      <hc_freetext>Breast Cancer</hc_freetext>
      <i_freetext>A:Immune reconstitution of autologous dendritic cells transfusion after high-dose chemotherapy with autologous hematopoietic stem cells support  ;B:Immune reconstitution of selective autologous lymphocyte transfusion with regulatory T cells depletion after high-dose chemotherapy with autologous hematopoietic stem cells support  ;C:Immune reconstitution of cytokine IL-2 and IFN after high-dose chemotherapy with autologous hematopoietic stem cells support  ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Jun Jia</firstname>
        <middlename />
        <lastname />
        <address>52 Fucheng Road, Haidian District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100142</zip>
        <telephone>+86 010 88196931</telephone>
        <email>jiajun@bjcancer.org</email>
        <affiliation>Beijing Cancer Hospital/Peking University School of Oncology</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Jun Ren</firstname>
        <middlename />
        <lastname />
        <address>52 Fucheng Road, Haidian District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100142</zip>
        <telephone>+86 010 88196356</telephone>
        <email>renjun@bjcancer.org</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1) Breast cancer patients with metastatic or relapsed disease proved by histopathology or cytology;
2) Aged between 18 and 70, male or female;
3) With measurable tumor mass &gt;=10mm by ultrasonic examination, CT or MR scans;
4) ECOG Performance Status &lt;=2 and Expectant survival &gt;3months;
5) An interval of at lest 4 weeks from the last operation, radiation therapy and chemotherapy;
6) With normal marrow function and the peripheral blood test before treatment should in following range: WBC between 4.0*10^9/L to 10*10^9/L, Hb concentration between 95g/L to 165g/L, PLT concentration between 75*10^9/Lto 300*10^9/L7) Normal liver and kidney function;
8) With normal heart function and no history of heart failure. Electrocardiogram exam is normal;
9) No history of severe hypersensitive constitution and allergy to taxane and cytokines such as IL-2, GM-CSF, and IFN etc.;
10) Without infection diseases or skin infectious sites;
11) Patients with good compliance and agree to follow-up after treatment;
12) Inform of consents were signed voluntarily.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>70</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1) Not measurable tumor or only bone metastasis;
2) ECOG Performance Status &gt; 2 and Expectant survival &lt; 3 months;
3) Patients having operation, radiotherapy, chemotherapy within 4 weeks;
4) Pregnant or lactated women;
5) Patients with history of congestive heart failure;
6) Patients with extensive pulmonary fibrosis or respiratory failure;
7) Dysfunction of liver or kidney (ALT, AST, Cr, and BUN raise over 1.5 times of upper limit of normal);
8) Myeloproliferative disorder or marrow metastasis;
9) With infection diseases or skin infectious sites;
10) Patients with severe cerebrovascular disease or brain metastases that affect describing the state of illness;
11) Hypersensitive constitution or allergy to taxane and cytokines such as IL-2, IFN, and GM-CSF etc;
12) Patients refuse to sign informed consent.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>progression-free survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>adverse reaction events;objective response rate;Overall Survival;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Beijing Medicine Research and Development Fund</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2007-08-21</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>